BioMarin Pharmaceutical Inc (NASDAQ:BMRN) Accelerates Growth After Amicus Deal, Faces Near-Term Repricing
![]() |
Acquisition-fueled revenue momentum and fresh clinical readouts push top-line trajectory higher, while stretched multiples and an above-target momentum oscillator signal near-term price compression risk. |










